课题基金 / 基金详情

MUTATION AND GENETIC ANALYSIS OF NEUROFIBROMATOSIS

MUTATION AND GENETIC ANALYSIS OF NEUROFIBROMATOSIS
神经纤维瘤病的突变和遗传分析
批准号:
2416320
负责人:
Margaret R Wallace
金额:
$9.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-05-01 至 1999-04-30

项目摘要

项目成果

Margaret R Wallace的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Neurofibromatosis type 1 (NF1) is among the most prevalent of human genetic diseases, with a frequency of 1/3000 individuals in all ethnic groups. The major features include pigmented dermal regions, neurofibromas (benign tumors) arising from nerve sheaths, bone deformities, and hamartomata of the iris. Most patients are diagnosed in childhood or adolescence, as the symptoms tend to progress with age and hormonal surges. Medicine currently can only offer standard treatment of some individual symptoms - no cure or treatment to retard progression exists. The NF1 gene is an approximately 300 kb locus on chromosome 17 which is disrupted by constitutional mutations in NF1 patients. It is thought to be a tumor suppressor gene, based on phenotype being associated with loss of function. A widely accepted hypothesis suggests that loss or alteration of function from both NF l alleles in a cell (the other loss the result of somatic mutation, a "second hit") results in the phenotype. The long-term goal of this project is to identify NF1 gene mutations in order to answer specific questions regarding the genetics of the disorder, and to examine the two-hit hypothesis. First, it is important to define a set of mutations to categorize NF1 mutations by type and location within the gene, since very little mutational data currently lists. Secondly, the issue of penetrance is not clear-do all individuals with constitutional NF1 mutations express symptoms? Penetrance will be studied by identifying NF1 gene mutations in a series of "new mutation" families, as well as in families in which the transmission is not clearly autosomal dominant (such as multiple affected children from normal parents, or "skipped" generations). DNA and RNA will be analyzed by several molecular genetic techniques designed to detect mutations, including pulsed field electrophoresis, and PCR-based analysis of individual exons and cDNA fragments. This research may also provide a better estimate of the true rate of occurrence of "new mutation." In addition, two recent studies using linked markers suggest that a very high proportion of NF1 mutations arise in the paternal germline, unrelated to age. Parental origin of each new mutation identified in this study will be analyzed using polymorphisms within the coding regions of the NF1 gene itself. Any maternally-arising mutations will be the focus of further study, to investigate whether there are any characteristics that set them apart from paternally-derived mutations. To investigate the "two-hit" hypothesis, mutational analysis will be performed on the DNA from blood and from several physically separate neurofibromas from the each of several patients. Discovery of the same constitutional mutation yet different "second" mutations in each tumor would verify the tumor suppressor hypothesis. The data from these studies will significantly contribute to research into the function of the NF1 gene and the mutation data base, which will be useful for development of DNA diagnosis and further NF1 research.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
Somatic mosaicism in a patient with neurofibromatosis type 1.
1 型神经纤维瘤病患者的体细胞镶嵌。
DOI: --
发表时间: 1996
期刊: American journal of human genetics
影响因子: 9.8
作者: [Colman,SD, Rasmussen,SA, Ho,VT, Abernathy,CR, Wallace,MR]
通讯作者: Wallace,MR
DOI: 10.1038/onc.2016.464
发表时间: 2017-06-01
期刊: Oncogene
影响因子: 8
作者: [Pemov A, Li H, Patidar R, Hansen NF, Sindiri S, Hartley SW, Wei JS, Elkahloun A, Chandrasekharappa SC, NISC Comparative Sequencing Program, Boland JF, Bass S, NCI DCEG Cancer Genomics Research Laboratory, Mullikin JC, Khan J, Widemann BC, Wallace MR, Stewart DR]
通讯作者: Stewart DR
Genetic Dissection of Tumor Progression in NF-1 AML
  • 批准号:
    6892300
  • 项目类别:
  • 资助金额:
    $25.9万
  • 财政年份:
    2002
  • 负责人:
    Margaret R Wallace
  • 依托单位:
Genetic Dissection of Tumor Progression in NF-1 AML
  • 批准号:
    6786652
  • 项目类别:
  • 资助金额:
    $25.88万
  • 财政年份:
    2002
  • 负责人:
    Margaret R Wallace
  • 依托单位:
Genetic Dissection of Tumor Progression in NF-1 AML
  • 批准号:
    6623691
  • 项目类别:
  • 资助金额:
    $25.81万
  • 财政年份:
    2002
  • 负责人:
    Margaret R Wallace
  • 依托单位:
MUTATION AND GENETIC ANALYSIS OF NEUROFIBROMATOSIS
  • 批准号:
    2269473
  • 项目类别:
  • 资助金额:
    $8.89万
  • 财政年份:
    1993
  • 负责人:
    Margaret R Wallace
  • 依托单位:
国内基金
海外基金
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    程子译
  • 依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
  • 批准号:
    2026JJ81091
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    刘亮
  • 依托单位:
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
  • 批准号:
    2026JJ50010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    应站明
  • 依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
  • 批准号:
    JCZRLH202600588
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: